FIELD: pharmaceutics.
SUBSTANCE: described is a pharmaceutical composition in form of a suppository, rectal or vaginal characterised by the fact that it contains as an active substance sodium salt of deoxyribonucleic acid and lipophilic base. Said base contains cocoa butter or cocoa butter alloys with paraffin or wax, or hydrogenated fat or vegetable and animal hydrogenated fats, or solid fat in the form of a mixture of lauric acid mono-, di- and triglycerides, or lanol, or alloys hydrogenated fats with wax or a solid paraffin at specified ratio. Also described is a method for preparing the composition.
EFFECT: invention provides high stability during storage at maintaining sufficient bioavailability for effective action.
3 cl, 3 tbl, 5 ex
Title | Year | Author | Number |
---|---|---|---|
MEDICAL PRODUCT AND MEDICINAL COMPOSITION FOR MANUFACTURING THEREOF | 2008 |
|
RU2372933C1 |
PHARMACEUTICAL ANTI-HERPETIC COMPOSITION | 2004 |
|
RU2291690C2 |
SUSTAINED RELEASE PHARMACEUTICAL COMPOSITION IN THE FORM OF A SUPPOSITORY CONTAINING HEXAPEPTIDE | 2020 |
|
RU2737800C1 |
CYCLOPHERONE-BASED PHARMACEUTICAL COMPOSITION OF LOCAL OR EXTERNAL APPLICATION FOR TREATMENT OF PURULENT-DESTRUCTIVE AFFECTION OF MUCOUS MEMBRANE AND SKIN, GENERAL-SYSTEM DISEASES IN CASE OF IMMUNODEFICIENCY CONDITIONS (VERSIONS) | 2008 |
|
RU2414221C2 |
SUPPOSITORIES WITH SODIUM AMINODIHYDROPHTHALAZINEDIONE | 2020 |
|
RU2760262C1 |
COMPOSITION FOR PREVENTING OR TREATING PROCTOLOGICAL DISEASES | 2022 |
|
RU2814279C2 |
COMPOSITION FOR TREATING TUBERCULOSIS | 2001 |
|
RU2185168C1 |
TOPICAL AND EXTERNAL TILORONE PHARMACEUTICAL COMPOSITION FOR TREATMENT OF PURULENT-DESTRUCTIVE MUCOSAL AND SKIN DISEASES, SYSTEMIC DISEASES IN IMMUNODEFICIENCY STATES | 2008 |
|
RU2401104C2 |
DERINAT SUPPOSITORIES TO BE USED IN MEDICAL PRACTICE | 2009 |
|
RU2429854C2 |
STABILISED IMMUNE-CORRECTIVE DRUG VIFERON-FORTE FOR TREATING INFECTIOUS-INFLAMMATORY DISEASES | 2008 |
|
RU2381812C1 |
Authors
Dates
2016-11-10—Published
2015-03-18—Filed